By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Key Statistics

Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO

Company News
Halozyme (HALO) Appoints Michael J. Labarre As Chief Scientific Officer 8/24/2015 7:51:12 AM
Halozyme (HALO) Reports Second Quarter 2015 Financial Results 8/11/2015 10:06:09 AM
University of California, San Francisco (UCSF) To Study Halozyme (HALO) PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery 8/6/2015 11:29:37 AM
Halozyme (HALO) Appoints Jeffrey W. Henderson To Board 8/6/2015 7:06:37 AM
Halozyme (HALO) To Host Second Quarter 2015 Financial Results Conference Call 8/4/2015 6:51:04 AM
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Sign Collaboration Agreement To Investigate Eribulin And PEGPH20 In Metastatic Breast Cancer 7/31/2015 11:06:32 AM
Halozyme (HALO) To Present At The JMP Securities 2015 Life Sciences Conference 6/22/2015 12:31:33 PM
Halozyme (HALO) Announces Plans For CFO Transition, Names Laurie Stelzer CFO 6/5/2015 7:24:52 AM
Halozyme (HALO) Shoots Up on News of $1B+ AbbVie (ABBV) Deal 6/3/2015 9:53:26 AM
Halozyme Therapeutics, Inc. (HALO) Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 6/1/2015 6:13:19 AM